Nisenberg Oleg, Pegg Anthony E, Welsh Patricia A, Keefer Kerry, Shantz Lisa M
Department of Cellular and Molecular Physiology, The Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, P.O. Box 850, 500 University Drive, Hershey, PA 17033, USA.
Biochem J. 2006 Jan 1;393(Pt 1):295-302. doi: 10.1042/BJ20051196.
The present study was designed to provide a better understanding of the role played by AdoMetDC (S-adenosylmethionine decarboxylase), the key rate-controlling enzyme in the synthesis of spermidine and spermine, in controlling polyamine levels and the importance of polyamines in cardiac physiology. The alphaMHC (alpha-myosin heavy chain) promoter was used to generate transgenic mice with cardiac-specific expression of AdoMetDC. A founder line (alphaMHC/AdoMetDC) was established with a >100-fold increase in AdoMetDC activity in the heart. Transgene expression was maximal by 1 week of age and remained constant into adulthood. However, the changes in polyamine levels were most pronounced during the first week of age, with a 2-fold decrease in putrescine and spermidine and a 2-fold increase in spermine. At later times, spermine returned to near control levels, whereas putrescine and spermidine levels remained lower, suggesting that compensatory mechanisms exist to limit spermine accumulation. The alphaMHC/AdoMetDC mice did not display an overt cardiac phenotype, but there was an increased cardiac hypertrophy after beta-adrenergic stimulation with isoprenaline ('isoproterenol'), as well as a small increase in spermine content. Crosses of the alphaMHC/AdoMetDC with alphaMHC/ornithine decarboxylase mice that have a >1000-fold increase in cardiac ornithine decarboxylase were lethal in utero, presumably due to increase in spermine to toxic levels. These findings suggest that cardiac spermine levels are highly regulated to avoid polyamine-induced toxicity and that homoeostatic mechanisms can maintain non-toxic levels even when one enzyme of the biosynthetic pathway is greatly elevated but are unable to do so when two biosynthetic enzymes are increased.
本研究旨在更深入地了解精脒和精胺合成中的关键限速酶——腺苷甲硫氨酸脱羧酶(AdoMetDC)在控制多胺水平方面所起的作用,以及多胺在心脏生理学中的重要性。使用αMHC(α-肌球蛋白重链)启动子来生成具有心脏特异性表达AdoMetDC的转基因小鼠。建立了一个始祖品系(αMHC/AdoMetDC),其心脏中AdoMetDC活性增加了100倍以上。转基因表达在1周龄时达到最大值,并在成年期保持恒定。然而,多胺水平的变化在出生后第一周最为明显,腐胺和精脒减少了2倍,精胺增加了2倍。在随后的时间里,精胺恢复到接近对照水平,而腐胺和精脒水平仍然较低,这表明存在补偿机制来限制精胺的积累。αMHC/AdoMetDC小鼠没有表现出明显的心脏表型,但在用异丙肾上腺素(“异丙基肾上腺素”)进行β-肾上腺素能刺激后,心脏肥大增加,同时精胺含量也略有增加。将αMHC/AdoMetDC与心脏鸟氨酸脱羧酶增加了1000倍以上的αMHC/鸟氨酸脱羧酶小鼠杂交,结果在子宫内致死,可能是由于精胺增加到有毒水平。这些发现表明,心脏中的精胺水平受到高度调节以避免多胺诱导的毒性,并且即使生物合成途径中的一种酶大幅升高,稳态机制也可以维持无毒水平,但当两种生物合成酶增加时则无法做到这一点。